30,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
15 °P sammeln
  • Broschiertes Buch

Internal tandem duplications in the FLT3 receptor gene (FLT3-ITD) are found in approximately 30% of patients with acute myeloid leukemia (AML). This oncogene influences various functions of the AML cell and leads to uncontrolled proliferation. Clinically, FLT3-ITD is associated with a poor prognosis in patients with AML. In this study, the influence of FLT3-ITD on the phosphatase CDC25C, which as a cell cycle regulator significantly influences the control of cell division, was investigated. The experiments described here showed that CDC25C is phosphorylated by FLT3-ITD and activated in an…mehr

Produktbeschreibung
Internal tandem duplications in the FLT3 receptor gene (FLT3-ITD) are found in approximately 30% of patients with acute myeloid leukemia (AML). This oncogene influences various functions of the AML cell and leads to uncontrolled proliferation. Clinically, FLT3-ITD is associated with a poor prognosis in patients with AML. In this study, the influence of FLT3-ITD on the phosphatase CDC25C, which as a cell cycle regulator significantly influences the control of cell division, was investigated. The experiments described here showed that CDC25C is phosphorylated by FLT3-ITD and activated in an uncontrolled manner. In the leukemia cell model, a primarily protective effect of CDC25C was shown in the presence of oncogenic stress. The genetically non-intact cells were increasingly prevented from dividing by CDC25C. However, the simultaneous presence of the FLT3-ITD mutation resulted in a loss of this protective function. The significance of the mechanism described here therefore lies in the control of the response of the leukemia cell to damage within the DNA. However, CDC25C does not have an oncogenic function in the classical sense.
Autorenporträt
Florian Perner studied human medicine and completed his doctorate in Magdeburg between 2009-2016. At the University of Jena, he began his further training as a specialist in internal medicine and research work in the Department of Hematology and Oncology. Since April 2018, Mr. Perner has been working at the Dana-Farber Cancer Institute at Harvard University in Boston.